Mirum president sells shares after RSU vesting

Mirum Pharmaceuticals’ president and COO Peter Radovich reported routine equity transactions.

Rhea-AI Filing Summary

Mirum Pharmaceuticals’ president and COO Peter Radovich reported routine equity transactions. On January 23, 2026, 5,750 restricted stock units vested and were converted to 5,750 shares of common stock at an exercise price of $0, increasing his directly held common shares to 26,429.

On January 26, 2026, he sold 3,143 shares of common stock at $96.192 per share, mainly to cover tax withholding on the vesting. After these transactions, he directly owned 23,286 shares of Mirum common stock and 5,750 restricted stock units, which continue to vest in thirds on each anniversary of January 23, 2024.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Radovich Peter

Role PRESIDENT AND COO

Sold 3,143 shs ($302K)

Approx. gross sale proceeds $302K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	3,143	$96.192	$302K
Exercise	Restricted Stock Units	5,750	$0.00	$0.00
Exercise	Common Stock	5,750	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 5,750 contracts (Direct); Common Stock — 23,286 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
2. F2. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
3. F3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

FAQ

What insider transactions did Mirum Pharmaceuticals (MIRM) report for Peter Radovich?

Mirum Pharmaceuticals reported that president and COO Peter Radovich had 5,750 restricted stock units vest into common shares, then sold 3,143 shares. The sale primarily covered tax withholding tied to the RSU vesting, while he retained a significant shareholding.

How many Mirum (MIRM) shares did Peter Radovich sell and at what price?

Peter Radovich sold 3,143 shares of Mirum common stock at $96.192 per share on January 26, 2026. According to the footnote, these shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

How many Mirum (MIRM) shares does Peter Radovich own after these transactions?

After the reported transactions, Peter Radovich directly owned 23,286 shares of Mirum common stock and 5,750 restricted stock units. These RSUs give him the right to receive an equal number of shares or cash, at the company’s discretion, as they vest over time.

What happened to Peter Radovich’s Mirum (MIRM) restricted stock units on January 23, 2026?

On January 23, 2026, 5,750 restricted stock units for Peter Radovich vested and were exercised at an effective price of $0 per unit. Each vested RSU converted into one share of Mirum common stock, increasing his directly held share count before the tax-related sale.

How do Peter Radovich’s Mirum (MIRM) restricted stock units vest over time?

The filing states that one-third of the RSUs vest on each anniversary of January 23, 2024, the vesting commencement date. This schedule means the entire award becomes fully vested on the three-year anniversary of that date, assuming continued service and plan conditions.

Is Peter Radovich considered an insider at Mirum Pharmaceuticals (MIRM)?

Yes. Peter Radovich is identified as an officer of Mirum Pharmaceuticals, serving as president and COO. As a company officer, he is classified as an insider under Section 16 reporting rules and must disclose transactions in company equity securities on Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Radovich Peter

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND COO

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		M		5,750	A	(1)	26,429	D
Common Stock	01/26/2026		S(2)		3,143	D	$96.192	23,286	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/23/2026		M			5,750	(3)	(3)	Common Stock	5,750	$0	5,750	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

2. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

	/s/ Judit Ryvkin, Attorney-in-Fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.